menu
    • menu

    Company profile for MeiraGTx

    NEW Drugs in Dev: 10
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    MeiraGTx is a clinical-stage gene therapy company focused on developing potentially curative treatments for patients living with serious diseases. We currently have six programs in clinical development including four ocular indications, a salivary gland condition, and a Parkinson’s disease program. Our initial focus on diseases of the eye, salivary gland and central nervous system is based on the significant unmet medical ne...
    MeiraGTx is a clinical-stage gene therapy company focused on developing potentially curative treatments for patients living with serious diseases. We currently have six programs in clinical development including four ocular indications, a salivary gland condition, and a Parkinson’s disease program. Our initial focus on diseases of the eye, salivary gland and central nervous system is based on the significant unmet medical need coupled with the high potential gene therapy has to provide meaningful clinical benefit in these areas. With headquarters in New York and London, our global footprint provides us the opportunity to partner with.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    MeiraGTxUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    450 East 29th Street, 14th Floor New York, NY 10016
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://meiragtx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/meiragtx/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/OlatecThera

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ZipBio, MeiraGTx Ink AAV Deal for Geographic Atrophy
    ZipBio, MeiraGTx Ink AAV Deal for Geographic Atrophy

    03 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/zipbio-and-meiragtx-enter-into-exclusive-license-agreement-to-advance-first-in-class-aav-gene-therapy-for-geographic-atrophy-302676702.html

    PR NEWSWIRE
    03 Feb 2026
    Share Share
    Eli Lilly Signs Deal for MeiraGTx's Gene Therapy for Severe Eye
    Eli Lilly Signs Deal for MeiraGTx's Gene Therapy for Severe Eye

    10 Nov 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/lilly-bags-eye-catching-retinal-disease-gene-therapy-meiragtx-475m-deal

    FIERCE BIOTECH
    10 Nov 2025
    Share Share
    Hologen AI commits $430M to MeiraGTx Parkinson's gene therapy
    Hologen AI commits $430M to MeiraGTx Parkinson's gene therapy

    15 Mar 2025

    // PRESS RELEASE

    https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-enters-strategic-collaboration-hologen-ai-expedite

    PRESS RELEASE
    15 Mar 2025
    Share Share
    MeiraGTx's gene therapy improves motor function in Ph 2 trial
    MeiraGTx's gene therapy improves motor function in Ph 2 trial

    16 Oct 2024

    // FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/meiragtx-gene-therapy-improves-motor-function-and-quality-life-phase-2-parkinsons-trial

    FIERCEBIOTECH
    16 Oct 2024
    Share Share
    MeiraGTx Holdings Climbs On Asset Purchase Agreement With Janssen Pharma
    MeiraGTx Holdings Climbs On Asset Purchase Agreement With Janssen Pharma

    22 Dec 2023

    // NASDAQ

    https://www.nasdaq.com/articles/meiragtx-holdings-climbs-on-asset-purchase-agreement-with-janssen-pharma

    NASDAQ
    22 Dec 2023
    Share Share
    Sanofi pays $30M for first look at MeiraGTx data, shot at deals
    Sanofi pays $30M for first look at MeiraGTx data, shot at deals

    31 Oct 2023

    // Annalee Armstrong FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/sanofi-pays-30m-first-look-meiragtxs-data-and-shot-brew-deals

    Annalee Armstrong FIERCE BIOTECH
    31 Oct 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search